Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 17, 2024, by Jaguar Health, Inc., a Delaware corporation. The report details two material corporate actions: the amendment of an existing At-the-Market (ATM) offering agreement and the implementation of a reverse stock split approved by stockholders at a special meeting on April 9, 2024.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on capital structure changes and financing agreements.
Material Changes
- ATM Offering Amendment: On May 23, 2024, the Company entered into the "Second ATM Amendment" with Ladenburg Thalmann & Co. Inc. This amendment removed the previous $75,000,000 aggregate offering limit on shares of common stock. Future issuances are now limited solely by specific constraints outlined in the amendment rather than a fixed dollar cap.
- Reverse Stock Split: The Board approved a one-for-sixty (1:60) reverse stock split. This action became effective at 12:01 am Eastern Time on May 23, 2024. Every 60 shares of pre-split common stock were reclassified into one share. The split also proportionally adjusted the conversion and exercise prices of outstanding non-voting common stock, options, and warrants, and reduced the number of shares reserved for equity compensation plans.
- Trading Adjustments: Commencing May 23, 2024, trading on The Nasdaq Capital Market resumed on a reverse stock split-adjusted basis under the new CUSIP number 47010C805.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. The primary risk disclosed relates to the structural changes in the Company's equity, including the reduction in share count and the adjustment of derivative securities. The Company noted that no fractional shares would be issued; instead, stockholders entitled to fractional shares will receive cash payments in lieu thereof.
Investor Verification Checklist
- Verify the new CUSIP number (47010C805) for post-split trading.
- Confirm the adjusted share count and price per share following the 1:60 reverse split.
- Review the specific limitations on the amended ATM offering agreement (Exhibit 10.1) to understand the new constraints on share issuance.
- Check the status of fractional share cash payments if applicable to your holdings.
- Confirm the adjusted exercise prices for any outstanding stock options or warrants held.